This paper presents the BioShuttle platform as a delivery vehicle for transfer of contrast agents and genetic material into target cells, which can be followed by activation of the BioShuttle inside the target cell.
Introduction
Diagosis and treatment planning of prostate cancer is challenging because, in most cases, the tumour inside the prostate is not visualized to the full extent using imaging modalities, such as CT (computed tomography) and MRT (magnetic resonance tomography). In addition, further advancing of the cancer through microscopic lymphatic or metastatic spread is not visible using these methods. Functional modalities of imaging, such as FDG (fluorodeoxyglucose)-PET (positron emission tomography) or choline-PET are improving, but they currently display a lack of imaging specificity ( Figure 1 ) [1, 2] .
Modern precise radiotherapeutic techniques allow high doses of radiation into tumours while preserving normal tissue from damage, but they require information about the extent of the tumour [3, 4] . An increasing number of highly specific drugs, drug formulations and diagnostic agents for molecular imaging are promising, but their physicochemical properties demand appropriate delivery systems. An increase in the use of non-invasive methods could represent solutions for molecular therapies and diagnostics at the molecular level, as shown by molecular imaging [5] . The successful use of new anticancer agents and prospective pharmaceutical diagnostic tools depends on their proven quality.
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modules for tumour-targeted delivery of a therapeutic gene [e.g. phNIS-EGFP vector containing NIS (sodium-iodide symporter) and EGFP (enhanced green fluorescent protein) as a twin-reporter gene] or an intracellular diagnostic agent. The data suggest that efficient and safe delivery, which is required for genetic interventions, has been achieved. Several issues hampered a possible breakthrough in gene delivery. These include the risk of inflammatory reactions, inefficient transport strategies and the unexplained specific local gene activation and its expression rate in the target tissue.
Recent progress in target-cell-and target-tissue-directed delivery of therapeutic genetic material, as well as in the field of molecular imaging, is based on the development of in vitro and in vivo carrier systems. These carrier systems can transport pharmacologically active substances or contrast agents into cells. The carrier systems could also facilitate recognition of cell-or tumour-specific gene expression profiles, to allow diagnostic testing or monitoring of the course of disease after therapeutic intervention.
The BioShuttle is a peptide-based modular delivery system
The BioShuttle [6] is composed of different functional domains, which are composed of at least two or three modular components ( Figure 2 ). These modules perform different tasks, such as facilitating cytoplasmic import, directing the shuttle through a subcellular 'zip code' and interacting with cargo, both diagnostic and therapeutic in nature. Potential cargo molecules include double-stranded DNA, siRNA (small intefering RNA), PNAs (peptide nucleic acids), opener/closer molecules, small drugs, antibodies, proteins and contrast agents. There is also a cleavable disulfide bond spacer between the cytoplasmic import module and the NLS (nuclear localization sequence). The spacer, when cleaved, activates the address module in the cytoplasm for the subcellular transport of the substance module. A second non-cleavable spacer, between the address module and the substance drug module, prevents steric interactions. This cleavage-resistant spacer also provides a coupling site for fluorescent markers and further active substances.
Transport of the BioShuttle across the cell membrane is temperature-and receptor-independent. The mechanism of transport is still unclear; the current theory suggests that transportation is mediated by formation of inverse micelles [7, 8] . An active transport system results in the delivery of cargo into subcellular compartments, such as the cell nucleus [9] .
Component-targeted subcellular transport for use in diagnostic imaging
The BioShuttle approach was inspired by data from the human genome project. The modular construction of the BioShuttle allows specific combinations of functional modules to be used, depending on the therapeutic and diagnostic requirements. The diagnostic version of the BioShuttle, to be used in molecular imaging of cell nuclei, could be facilitated by the following solution.
On the basis of current knowledge of the mode of action of transporter molecules involved in transmembrane transport, a BioShuttle was developed for intracellular contrast agent delivery in MRT. This CNN (cell nucleus-directed NLS)-BioShuttle is able to display cellular components, such as cell nuclei [10] . The knowledge of cell-specific gene expression profiles, which distinguish normal cells from diseased cells and tissues, resulted in the development of the ACGT (antisense-conjugated gadolinium transporter)-BioShuttle. This ACGT-BioShuttle displayed similar target cell specificity to that of the MRT contrast agent BioShuttle [11] . On the basis of these promising results, a further target was the imaging of gene expression in tumours which aberrantly express CTSB (cathepsin B)-mRNA. This means that, using the ACGT-BioShuttle, intravital molecular imaging at the transcriptional level is possible.
BioShuttle-mediated plasmid transfer (genetic intervention)
An attractive new approach in the field of the target-directed delivery of therapeutic genetic molecules is BioShuttlemediated plasmid transfer. The requirements for safe and efficient transfer of inactivated plasmids resulted in modification of the transmembrane transport module.
This special variant of the BioShuttle exhibits distinctive features that differ from the original BioShuttle, but the modular character of the transporter is retained. Additionally, the connection of the plasmid with the BioShuttle must demonstrate stability during use of the BioShuttle in ADME (administration, distribution, metabolism and excretion). The plasmid connector must stay intact during distribution of the BioShuttle into the bloodstream and be protected against cellular metabolism until the shuttle is excreted from the target tissue.
The connection between the plasmid and the BioShuttle also needs to be cleavable, because the plasmid will be released from the BioShuttle carrier at the target site when it is used in conjunction with HIFU (high-frequency ultrasound) technology. Inactivation of the plasmid transcription was performed by hybridization of a PNA containing a nucleobase sequence. This nucleobase sequence is complementary to the noncoding regulatory pDNA sequence in the promotor region in the CMV (cytomegalovirus) which is 5 -upstream of the transcription initiation site. Hybridization occured by triple-helix formation (DNA-PNA-DNA). Dissociation of the helix is prevented by the presence of a specific clamp-PNA, which contains a PNA with an identical sequence, connected by a five-amino-acid linker (Gly-Gly-Lys-Gly-Gly). This clamp-PNA resulted in the formation of a quadruplex with the plasmid DNA, increasing the stability of the hybridized helix.
The PNA used was of a specific length to allow dissociation at 41
• C of the PNA-DNA-PNA-DNA hybrids, allowing transcription to occur. HIFU causes a local increase in temperature, which is restricted to the tumour and, under these conditions, the plasmid is separated from the BioShuttle carrier and from the promotor sequence. Transcription is then initiated, but the surrounding tissue remains unaffected and protected from the therapeutic agents.
Conclusions
The clamp-BioShuttle was developed and optimized as a non-invasive delivery system to allow both genetic material and gene expression-specific contrast agents to enter cells and tissues, while minimizing the adverse exposure of healthy tissue. After cell-specific activation, gene expression rates and intracellular distribution patterns were detected and measured by CLSM (confocal laser-scanning microscopy); the raw data were quantified using mathematical analyses.
BioShuttle carriers can therefore be considered a helpful tool and an important step forward in the development of technology for gene transfer, gene therapeutic approaches and for molecular diagnostics. Investigations into the use of the BioShuttle carrier in molecular imaging of prostate cancer are ongoing.
